The critical role played by induction of NO production and the oxidative burst in killing parasites has been well documented in recent years and was elegantly demonstrated in a Syrian hamster model which showed that the inability to produce NO due to a lack of iNOS expression resulted in the inability to control intracellular challenge studies. the onset of immunity. All vaccinated dogs developed a humoral response characterised by IgG2 production. More importantly, vaccinated dogs developed significantly stronger cell-mediated immunity responses than did control dogs. Vaccination induced specific cellular reactivity to soluble antigens, with a after co-culture with autologous lymphocytes (p?=?0.0014). These responses were correlated with induction of the NOS pathway and production of NO derivatives, which has been shown to be an important leishmanicidal mechanism. These results confirm that vaccination with LiESP/QA-21 induces an appropriate Th1-profile cell-mediated response within three weeks of completing the primary course, and that this response effectively reduces the parasite load in pre-infected macrophages response within three weeks of the administration of the vaccine, and provides a basis for the understanding of the mode of action of this new tool. Introduction Canine leishmaniasis, a vector-borne disease of dogs, is caused by in the Mediterranean basin and is a significant problem for the canine populace of endemic areas [1]. It is transmitted in the Mediterranean area by the bite of certain species of sand flies of the ((?=?studies propose that while iNOS activity can be considered as an essential effector mechanism to prevent multiplication of amastigotes, the NO derivative produced may have additional functions including immunoregulatory functions [22]. Because of this pivotal role for the immune system, several authors have expressed the opinion that an effective vaccine against canine leishmaniasis would be the best control strategy for both canine and human disease [7], [23]. Two canine vaccines have been available for some time now in Brazil [11]. However, until the recent launch of the LiESP/QA-21 vaccine (CaniLeish, Virbac, France), there were no vaccines against available in Europe. With any new vaccine, and especially one that is usually the first of its kind, it is important to understand as much as possible about the mechanism of its action around the dog’s immune response and to study known markers of resistance Col13a1 to disease. Indeed investigation of such parameters has recently been proposed as representing an important supplementary data set when assessing any candidate vaccine for canine leishmaniasis [11]. The aim of the study presented here was to follow selected humoral and cellular markers of the immune response in dogs vaccinated with LiESP/QA-21 vaccine during the establishment of the immune response, and specifically to assess if an effective Th1-dominated profile could be generated. Materials and Methods Ethics Statement The Virbac Ethical Committee approval confirms that this study was carried out in accordance with the G.R.I.C.E. Ethical Committee Regulation applied to animal experimentation guidelines (implemented in France in 2007). Animals’ Characteristics 20 conventional Beagle dogs (10 male and 10 female) aged 6 months +/?1week on the day of the first vaccination were randomly assigned to two groups (vaccinated and control) according to their weight, sex and litter of birth. There were 5 males and 5 females per group. All animals were previously vaccinated with conventional vaccinations against Distemper computer virus, Adenovirus, Parvovirus, Parainfluenza virus and Leptospira. They were Tadalafil housed in controlled conditions, and dewormed with nitroscanate (Troscan, Virbac, France) 1 week prior to the date of the first administration of the LiESP/QA-21 vaccine. Vaccine and Vaccination Protocol The LiESP/QA-21 vaccine is usually authorised in the European Union under the trade name CaniLeish (Virbac, France). It is composed of purified excreted-secreted proteins of (LiESP), produced by means of a patented cell-free, serum-free culture system invented by the IRD (Institut de Recherche pour le Dveloppement) [24], and adjuvanted with QA-21, a highly purified fraction of the saponin. The doses used in this study were formulated at 100 gESP and 60 g QA-21. This is usually consistent with the minimum accepted levels in commercially available doses. Dogs in the vaccinated group were Tadalafil given one dose of the LiESP/QA-21 vaccine every 21 days for a total of three doses. Dogs in the control group did not receive any vaccination. Analyses and Schedule Serology testing of the humoral immune response ELISA testing was performed on the day of each vaccination (D0, D21, D42) and also two weeks after the last vaccine (D56) to dose the level of IgG1 and IgG2 antibodies to both LiESP and also specifically to Parasite Tadalafil Surface Antigen (PSA), which is a major antigenic component of LiESP. Blood was collected in uncoated tubes and the serum separated before performing the analyses. Briefly, the technique is performed as follows. A NUNC Maxisorp plate is coated with either 0.1 g ESP or 0.1 g PSA per well in.